21418-62-2

Upstream product

• 22737-54-8 2,3-dioxo-1-p-tolylpiperidine-4-carbonitrile 
• 1021088-60-7 4-(4-methylphenylamino)butyronitrile 
• 106-49-0 p-toluidine 

Downstream Products

• 1448687-19-1 C₂₀H₁₉ClN₄O₃S 
• 1448687-11-3 C₁₉H₁₇FN₄O₃S 
• 1448687-10-2 C₁₉H₁₈N₄O₃S 
• 1353278-69-9 3-amino-1-{(4-phenylpiperazin-1-yl)propanoyl}-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-81-5 3-amino-1-[3-{4-(4-tert-butylbenzyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 1353278-73-5 3-amino-1-[{4-((benzo[d][1,3]dioxol-5-yl)methyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-85-9 3-amino-1-[{4-(2,3,4-trimethoxybenzyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-76-8 3-amino-1-[{4-(2,4,6-trimethylbenzyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353279-30-7 3-amino-1-{4-(2-pyridinylpiperazin-1-yl)propanoyl}-6-N-p-tolyl-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-89-3 3-amino-1-[{4-(4-chlorophenyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-92-8 3-amino-1-[{4-(4-methoxyphenyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1353278-71-3 3-amino-1-[3-{4-(2,4-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-one 
• 1353278-65-5 3-amino-1-[{4-(2,3-dimethylphenyl)piperazin-1-yl}propanoyl]-6-N-(p-tolyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one 
• 1346756-68-0 1-N-t-butoxycarbonyl-3-amino-4,5,6,7-tetrahydro-6-N-(p-tolyl)pyrazolo[3,4-c]pyridin-7-one 

Relevant academic research and scientific papers

Synthesis and the 5-HT6 receptor antagonistic effect of 3-arylsulfonylamino-5,6-dihydro-6-substituted pyrazolo[3,4]pyridinones for neuropathic pain treatment

A novel series of 3-arylsulfonylamino-5,6-dihydro-6-substituted-1H- pyrazolo[3,4-c]pyridine-7-ones was designed and synthesized as 5-HT6 ligands. Among the derivatives synthesized, the lead compound, 12b, having piperidine functionality at the 6-position and (1-naphthyl)sulfonamino at the 3-position of the core structure showed the most potent 5-HT6 inhibitory activity in vitro, good stability without CYP liability, and good neuropathic pain alleviation activity in a rat animal model.

Synthesis of 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7- one derivatives and evaluation of their anticancer activity

Promising anticancer compounds of the type 1,6-disubstituted 4,5,6,7-tetrahydropyrazolo[3,4-c]pyridin-7-ones were identified. The target compounds were readily synthesized in a large scale via a sequence of reactions starting from the commercially available primary amines. Their in vitro anti-proliferative activity has been evaluated on prostate (DU-145), colon (HT-29 and HCT-116) and melanoma (A375P) human cancer cell lines. The relationships between the structure and the anticancer activity, covering all tested cancer cell lines, revealed that the compound 5c with 2,4-dimethylphenyl substituent at R2 was the most potent with the IC50 values in the range as low as 0.16 to 0.40 μM.

NOVEL 1,6-DISUBSTITUTED-3-AMINO-4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE COMPOUNDS AND PREPARATION THEREOF

Provided are a novel 1,6-disubstituted-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridin-7-one compound, a pharmaceutically acceptable salt compound thereof, a method for preparing the compound, and an anticancer pharmaceutical composition including the compound as an effective ingredient.